Fowler's solution: Difference between revisions
Jump to navigation
Jump to search
imported>Hellbus mNo edit summary |
imported>Mfernflower No edit summary |
||
| Line 1: | Line 1: | ||
'''Fowler's solution''' | '''Fowler's solution''' consists of 1% [[potassium arsenite]] (KAsO<sub>2</sub>) in water and was first described and published as a potential treatment for [[malaria]] and [[syphilis]] in the late 1700s and was once also prescribed as a [[Pharmaceutical drug#For nutrition|tonic]].<ref>{{Cite journal |last1=Ho |first1=Derek |last2=Lowenstein |first2=Eve J. |date=2016 |title=Fowler's Solution and the Evolution of the Use of Arsenic in Modern Medicine|journal=Skinmed |volume=14 |issue=4 |pages=287–289 |issn=1540-9740 |pmid=27784519}}</ref><ref name=Jolliffe>{{cite journal | author = Jolliffe, D. M. | title = A history of the use of arsenicals in man | journal = Journal of the Royal Society of Medicine | year = 1993 | volume = 86 | issue = 5 | pages = 287–289 | doi = 10.1177/014107689308600515 | pmc = 1294007 | pmid=8505753}}</ref> Thomas Fowler (1736–1801) of [[Stafford]], England, proposed the solution in 1786 as a substitute for a [[patent medicine]], "tasteless [[fever|ague]] drop". From 1865, Fowler's solution was a [[leukemia]] treatment.<ref name=Jolliffe/><ref name=Doyle>{{cite journal | author = Doyle, Derek | title = Notoriety to respectability: a short history of arsenic prior to its present day use in haematology | journal = British Journal of Haematology | year = 2009 | volume = 145 | issue = 3 | pages = 309–317 | doi = 10.1111/j.1365-2141.2009.07623.x | pmid = 19298591 | s2cid = 6676910 | doi-access = free }}</ref> | ||
From 1905, inorganic arsenicals like Fowler's solution saw diminished use as attention turned to organic arsenicals, starting with [[Atoxyl]].<ref name='ITOM'>{{Cite book |last1=Gibaud |first1=Stéphane |last2=Jaouen |first2=Gérard |title=Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy |year=2010 |volume=32 |pages=1–20 |doi= 10.1007/978-3-642-13185-1_1|series=Topics in Organometallic Chemistry |bibcode=2010moc..book....1G |isbn=978-3-642-13184-4 }}</ref> | From 1905, inorganic arsenicals like Fowler's solution saw diminished use as attention turned to organic arsenicals, starting with [[Atoxyl]].<ref name='ITOM'>{{Cite book |last1=Gibaud |first1=Stéphane |last2=Jaouen |first2=Gérard |title=Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy |year=2010 |volume=32 |pages=1–20 |doi= 10.1007/978-3-642-13185-1_1|series=Topics in Organometallic Chemistry |bibcode=2010moc..book....1G |isbn=978-3-642-13184-4 }}</ref> | ||
As | As inorganic arsenic compounds are notably toxic and [[carcinogen]]ic—with side effects such as [[cirrhosis of the liver]], [[idiopathic]] [[portal hypertension]], [[bladder cancer|urinary bladder cancer]], and [[skin cancer]]s—Fowler's solution fell from use. In 2001, however, the U.S. [[Food and Drug Administration]] (FDA) approved a drug of [[arsenic trioxide]] to treat [[acute promyelocytic leukaemia]],<ref>{{ cite journal |author1=Zhu, J. |author2=Chen, Z. |author3=Lallemand-Breitenbach, V. |author4=de Thé, H. | title = How acute promyelocytic leukaemia revived arsenic | journal = [[Nature Reviews Cancer]] | year = 2002 | volume = 2 | issue = 9 | pages = 705–714 | doi = 10.1038/nrc887 | pmid = 12209159 |s2cid=2815389 }}</ref> and interest in arsenic chemistry has returned.<ref>{{cite journal | author1 = Chen, S. J. | author2 = Zhou, G. B. | author3 = Zhang, X. W. | author4 = Mao, J. H. | author5 = de Thé, H. | author6 = Chen, Z. | title = From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia | journal = Blood | year = 2011 | volume = 117 | issue = 24 | pages = 6425–6437 | doi = 10.1182/blood-2010-11-283598 | pmid = 21422471 | pmc = 3123014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 02:24, 19 October 2025
Fowler's solution consists of 1% potassium arsenite (KAsO2) in water and was first described and published as a potential treatment for malaria and syphilis in the late 1700s and was once also prescribed as a tonic.[1][2] Thomas Fowler (1736–1801) of Stafford, England, proposed the solution in 1786 as a substitute for a patent medicine, "tasteless ague drop". From 1865, Fowler's solution was a leukemia treatment.[2][3]
From 1905, inorganic arsenicals like Fowler's solution saw diminished use as attention turned to organic arsenicals, starting with Atoxyl.[4]
As inorganic arsenic compounds are notably toxic and carcinogenic—with side effects such as cirrhosis of the liver, idiopathic portal hypertension, urinary bladder cancer, and skin cancers—Fowler's solution fell from use. In 2001, however, the U.S. Food and Drug Administration (FDA) approved a drug of arsenic trioxide to treat acute promyelocytic leukaemia,[5] and interest in arsenic chemistry has returned.[6]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".